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The development of antisense oligonucleotide therapy is an impor-
tant advance in the identification of corrective therapy for neuro-
muscular diseases, such as spinal muscular atrophy (SMA). Because
of difficulties of delivering single-stranded oligonucleotides to the
CNS, current approaches have been restricted to using invasive
intrathecal single-stranded oligonucleotide delivery. Here, we report
an advanced peptide-oligonucleotide, Pip6a-morpholino phosphor-
odiamidate oligomer (PMO), which demonstrates potent efficacy in
both the CNS and peripheral tissues in severe SMA mice following
systemic administration. SMA results from reduced levels of the
ubiquitously expressed survival motor neuron (SMN) protein be-
cause of loss-of-function mutations in the SMN1 gene. Therapeutic
splice-switching oligonucleotides (SSOs) modulate exon 7 splicing of
the nearly identical SMN2 gene to generate functional SMN protein.
Pip6a-PMO yields SMN expression at high efficiency in peripheral
and CNS tissues, resulting in profound phenotypic correction at
doses an order-of-magnitude lower than required by standard na-
ked SSOs. Survival is dramatically extended from 12 d to a mean of
456 d, with improvement in neuromuscular junction morphology,
down-regulation of transcripts related to programmed cell death
in the spinal cord, and normalization of circulating insulin-like
growth factor 1. The potent systemic efficacy of Pip6a-PMO, target-
ing both peripheral as well as CNS tissues, demonstrates the high
clinical potential of peptide-PMO therapy for SMA.
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Spinal muscular atrophy (SMA), a leading genetic cause of infantmortality primarily due to lower motor neuron degeneration
and progressive muscle weakness, results from loss of the ubiquitous
survival motor neuron 1 gene (SMN1) (1, 2). Humans have a second
nearly identical copy, SMN2, that differs from SMN1 by a crucial
nucleotide transition within exon 7 leading to the predominant
generation of an alternative exon 7-excluded transcript and only
marginally functional protein (3–7). SMN2 therefore fails to
compensate for loss of SMN1 unless sufficient copies are present
to generate functional levels of full-length SMN protein (2).
A rational, gene therapy-based approach for SMA uses single-
stranded antisense splice-switching oligonucleotides (SSOs) to
enhance SMN2 pre-mRNA exon 7 inclusion via steric block of
splice regulatory pre-mRNA elements (8). Targeting the intron
splice silencer N1 (ISS-N1) site within intron 7, by deletion or SSO-
mediated splice switching, improves exon 7 inclusion (9, 10). ISS-
N1–targeted SSOs used to treat presymptomatic severely affected
neonatal SMA mice, via systemic or intracerebroventricular ad-
ministration, extend survival from 10 to >100 d (11, 12). Although
SSO targeting to the CNS is essential, there is also evidence for a
peripheral role for the SMN in SMA (13–24).
Although SSO therapy is currently at an advanced stage of de-
velopment and one of the most promising approaches for SMA, a
major challenge is efficient delivery. The current generation of
SSOs does not cross the blood–brain barrier and must be admin-
istered by repeated intrathecal injection. Although this mode of
administration appears to be safe, nearly a third of treated patients
experience the typical side effects associated with lumbar puncture,
and patients who develop scoliosis, which frequently occurs in SMA,
pose additional challenges associated with lumbar puncture (25). To
improve delivery of neutrally charged SSOs dramatically, we have
developed an advanced phosphorodiamidate oligomer (PMO) in-
ternalizing peptide (Pip) peptide delivery technology. Pip peptides
are covalently conjugated (26, 27) and capable of SSO delivery to a
variety of adult tissues, including liver, kidney, skeletal muscle, di-
aphragm, and heart (26, 28–30). Here, we report that a highly active
peptide, Pip6a, directly conjugated to a morpholino PMO permits
highly efficient systemic delivery, which enhances bodywide SMN
expression, including in brain and spinal cord; rescues the pheno-
type; and dramatically prolongs the life span of severe SMA mice.
These data demonstrate powerful SMA disease modification by
peptide-PMO therapy, a benefit that could be extended to many
other neurodegenerative disorders (8, 31, 32).
Results
Systemic Pip6a-PMO Treatment of Severe SMA Mice Rescues the
Disease Phenotype and Enhances Survival. Pip6a, our lead de-
livery peptide (28, 29), was directly conjugated to a 20-mer PMO
sequence targeting the ISS-N1 element of SMN2 intron 7 (12).
We evaluated the efficacy of Pip6a-PMOs in vitro using the
neuroblastoma cell line SH-SY5Y, which resulted in a significant
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dose-dependent increase of full-length SMN2 (FLSMN2) expres-
sion (Fig. S1A). By contrast, PMO alone failed to increase FLSMN2
expression even at the highest dose of 500 nM (Fig. S1B). Pip6a is
thus able to improve cellular uptake of PMO by neurons.
For in vivo studies, we used the Taiwanese severe SMA model
(33). Pups were treated at postnatal day 0 (PND0) with a single
dose of 10 μg/g of PMO or Pip6a-PMO via the facial vein. Sur-
vival was recorded until the humane end point was reached.
Untreated and saline-treated SMA mice survived a median of
12 d, as is typical of this model (34) (Table S1). PMO-treated
mice showed no change in survival, whereas Pip6a-PMO–treated
mice survived a median of 167 d (Fig. 1A and Table S1).
Pip6a-PMO–treated pups were significantly heavier than their
untreated or PMO-treated littermates from day 7 (Fig. 1B).
Movement and coordination were tested via the natural response
to negative geotaxis. A greater percentage of Pip6a-PMO–treated
pups were able to turn upright by day 8 compared with either
untreated or PMO-treated pups (Fig. S2). Muscle strength was
tested by the hind-limb suspension tube test scoring system (35).
Pups treated with 10 μg/g of PMO were not significantly different
from untreated pups, whereas Pip6a-PMO–treated pups were
significantly stronger by day 12 (Fig. 1C).
Although only Pip6a-PMO–treated pups showed an improved
phenotype, both PMO- and Pip6a-PMO–treated pups demon-
strated significantly increased FLSMN mRNA and SMN pro-
tein expression in all tissues tested (Fig. 1 D and E). Insulin-like
growth factor 1 (IGF1) is a neurotrophic factor reduced in severe
SMA models (11, 36). Both Pip6a-PMO and PMO treatment
rescued IGF1 expression at PND7, with Pip6a-PMO restoring
IGF1 to levels found in unaffected littermates (Fig. 1F). Impaired
maturation of neuromuscular junctions (NMJs) is a hallmark
of SMA, notable by small endplate area and complexity, dener-
vation, poor terminal arborization, and neurofilament accumu-
lation at the presynaptic nerve terminal (37–41). We therefore
studied the morphology of NMJs in the transversus abdominis
(TVA), one of the most severely affected muscles, between un-
treated and treated SMA pups at PND12 (42). Here, we ob-
served the strongest difference between treatment groups. Pups
treated with Pip6a-PMO had far fewer denervated or partially
denervated NMJs, indicative of poor end-terminal arboriza-
tion, in comparison to PMO-treated or untreated SMA pups
(Fig. 1 G and H). Although significantly greater than in un-
treated SMA pups, both treatments resulted in similar restoration
of postsynaptic motor endplate areas (Fig. 1I). In this side-by-side
Fig. 1. Direct comparison of PMO versus Pip6a-PMO administration in severe SMA mice. (A) Survival curves for SMA untreated (n = 9) pups and for SMA pups
administered 10 μg/g PMO (n = 20) or 10 μg/g of Pip6a-PMO (n = 9). Pip6a-PMO treatment significantly enhanced survival (mean of 196.4 ± 114.9, median of
167 d) (P ≤ 0.0001, log-rank Mantel–Cox test). (B) Weights of treated and untreated severe SMA pups plotted as mean ± SEM. Pip6a-PMO–treated pups
weighed significantly more than SMA untreated pups starting from PND7 (*P ≤ 0.005, Student’s t test). (C) Hind-limb suspension score plotted as mean ± SEM
(***P = 3.55 × 10−13, Fisher’s tests with significance after Bonferroni correction). (D) Protein in tissues analyzed by Western blots for human SMN and mouse
β-tubulin. SMN expression of untreated SMA pups was normalized to 1 for comparative expression. (E) RNA expression of FLSMN transcript analyzed by
quantitative RT-PCR related to “total SMN” transcripts, represented by exon 2a and 2b amplicons. The expression of FLSMN in each untreated SMA tissue was
normalized to 1 for comparative expression. (F) Circulating serum levels of IGF1 determined by murine IGF1 ELISA plotted as mean ± SEM. Statistical sig-
nificance was determined by one-way ANOVA with multiple comparisons (*P ≤ 0.01). n.s., not significant. (G) Representative confocal images of NMJs at
PND12. Several defects of the NMJs were observed in SMA untreated and PMO-treated pups, including neurofilament accumulation (white arrow), de-
nervated endplates (white arrowhead), and reduced terminal arborization (open arrowhead). Also observed in all treated and untreated pups, although not
quantified, were multiinnervated endplates, indicative of normally developing NMJs (open arrow). Postsynaptic endplates were stained in red (α-bungar-
otoxin) and neurons were stained in green in neurofilament (2H3) and synaptic vesicles (SV2). (Scale bars, 10 μm.) (H) Percentage of NMJs scored as partially or
fully denervated. (I) Postsynaptic areas were quantified using ImageJ. In D, E, H, and I, data are represented as mean ± SEM (*P ≤ 0.05; **P ≤ 0.01; ***P ≤
0.001 by Student’s t test in comparison to untreated SMA mice).











comparison using a low dose of compounds, Pip6a-PMO was
clearly better able to correct the SMA phenotype over naked
PMO-treated mice.
Pip6a-PMO Treatment Demonstrates Dose-Dependent Phenotypic
Rescue and Enhanced Survival. As established above, pups treated
with a single dose of 10 μg/g of Pip6a-PMO survived a median
of 167 d. We next evaluated lower doses of Pip6a-PMO, dem-
onstrating that survival of treated pups was dose-dependent.
Untreated mice survived a median of 12 d, whereas a single
dose of 5 μg/g of Pip6a-PMO improved median survival to 55 d
(Fig. 2A and Table S1). Furthermore, Pip6a-PMO–treated ani-
mals receiving a single 2.5-μg/g dose survived a median of 33 d,
whereas no increase in survival was recorded for pups treated
with a 1-μg/g dose (Table S1). Reduced doses of 2.5 and 5 μg/g of
Pip6a-PMO still improved weight, muscle strength, movement,
and coordination over untreated SMA pups (Fig. S3). Delayed
onset of peripheral ear and tail necrosis, a characteristic patho-
logical finding in this model, was also found to be dose-dependent
(Table S2).
Several seminal studies have reported that using two doses
of SSOs confers stronger phenotypic improvements than single
doses (11, 43, 44). We therefore treated severe SMA pups at
PND0 and PND2 with our most effective doses of Pip6a-PMO
(5 and 10 μg/g), as well as 10 μg/g of Pip6a-PMO scrambled and
10 μg/g of naked PMO. Two doses of scrambled Pip6a-PMO
showed no improvement on survival (Table S1). Median survival
of pups treated with two doses of naked PMO was improved over
single-dose treatment (median survival of 54 d and 11.5 d, re-
spectively) (Table S1). The second dose of naked PMO also
moderately improved weight and motor function (Fig. S4). By
contrast, all mice treated with two doses of 5 or 10 μg/g of Pip6a-
PMO survived at least 200 d, with median survivals of 283 and
457 d, respectively, the greatest life span extension published for
any SSO-based therapy to date (Fig. 2B and Table S1). Impor-
tantly, doubling the doses did not generate a toxic response in
these pups. Indeed, analysis of serum markers for liver and kidney
toxicity revealed no differences between treated and untreated SMA
pups 7 d postadministration (Fig. S5).
Early assessment of phenotypes after two doses of 5 and 10 μg/g
of Pip6a-PMO in SMA pups showed an overall improvement
over untreated pups (Fig. S6). Pre- and postweaning weights for
Pip6a-PMO–treated animals were greater than for untreated
groups, yet never reaching the pre- and postweaning weights of
unaffected littermates (Fig. S6 A and B). Response to negative
geotaxis was similar between unaffected littermates and Pip6a-
PMO–treated pups, with the majority of treated pups completing
the task by day 8. A much smaller percentage of untreated SMA
pups were able to complete the task, even by day 12 (Fig. S6C).
Hind-limb strength of Pip6a-PMO–treated pups was also similar
to unaffected littermates (Fig. S6D).
To elucidate molecular efficacy, SMN mRNA expression and
protein expression were determined in treated tissues (Fig. 2 C
and D). Spinal cord, brain, lower limb skeletal muscle, heart, and
liver were harvested at PND7, and FLSMN2 transcripts were
analyzed by quantitative PCR (qPCR), normalized to total SMN2
expression, whereas total SMN protein expression was determined
by Western blot. A dose-dependent increase of FLSMN2 mRNA
as well as SMN protein was observed in nearly all tissues of
mice treated with Pip6a-PMO. These results demonstrate that
the efficacy of Pip6a-PMO is dose-dependent and improves with
multiple administrations.
Pip6a-PMO Improves NMJ Structure and Innervation. We previously
described rescue of NMJ pathology in pups treated with 10 μg/g
of Pip6a-PMO. To understand further the dose-dependent im-
provement on phenotype of Pip6a-PMO–treated animals, we
analyzed the innervation and endplate area of NMJs from the
TVA of pups treated with the reduced dose of 5 μg/g compared
with 10 μg/g of Pip6a-PMO (Fig. 3). Severe SMA mice have
greater numbers of partially or fully denervated NMJs (45). A
single dose of 10 μg/g rescued NMJs to normal levels of in-
nervation, and NMJs from pups treated with 5 μg/g of Pip6a-
PMO also showed an improvement over untreated pups (Fig. 3B).
Similarly, postsynaptic endplate areas were significantly greater in
both treatment groups compared with SMA-affected mice (Fig.
3C). The extent of NMJ phenotypic correction therefore nicely
correlates with life span extension and Pip6a-PMO concentration.
Fig. 2. Dose-dependent Pip6a-PMO restoration of phenotype. (A) Survival curves for untreated severe SMA mice (n = 9) and for pups treated with a single
dose (PND0) of 2.5 μg/g of Pip6a-PMO (n = 11), 5 μg/g of Pip6a-PMO (n = 11), or 10 μg/g of Pip6a-PMO (n = 9). All administrations of Pip6a-PMO resulted in
statistically significant improvement of survival over untreated SMAmice (P ≤ 0.0001, log-rank Mantel–Cox text). (B) Survival curves for untreated severe SMAmice
(n = 9) and two doses (PND0/2) of 5 μg/g (n = 5) and 10 μg/g of Pip6a-PMO (n = 5). Both administrations with Pip6a-PMO resulted in statistically significant im-
provement of survival over untreated SMA mice (P ≤ 0.0001, log-rank Mantel–Cox test). (C) Protein expression of SMN in tissues following single PND0 (1×) or
double PND0 and PND2 (2×) administration of Pip6a-PMO. SMN protein was analyzed with Western blots for human SMN and mouse β-tubulin. SMN expression of
untreated SMA pups was normalized to 1 for comparative expression. (D) FLSMN2 transcript levels were measured by qPCR. Expression of FLSMN2 in each un-
treated SMA tissue was normalized to 1 for comparative expression. Samples are plotted as mean ± SEM, and statistical significance compared with untreated SMA
mice was determined by Student’s t test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).
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Loss of motor neurons in the spinal cord appears to be a late
feature of SMAmouse models, and there are no universally accepted
methods for quantifying motor neuron loss, hindering consistency
across different studies. The health of neurons in the spinal cord was
thus demonstrated by measuring two transcripts for apoptosis, TNF
receptor superfamily member 6 (fas) and phorbol-12-myristate-13-
acetate-induced protein 1 (Pmaip1), which are dysregulated in the
spinal cord of SMA mice (46). At PND7, spinal cords from un-
affected littermates expressed significantly lower transcript levels of
fas and Pmaip1 than spinal cords from SMA-affected pups (Fig. 3 D
and E). Treatment with a single dose of 5 or 10 μg/g of Pip6a-PMO
reduced their transcript levels, indicating that early treatment protects
against programmed cell death within the spinal cord.
Pip6a Delivers SSO to the CNS in Adult Mice. Although we have
achieved systemic delivery in early postnatal pups, targeting the
CNS of patients at all ages will be critical for a successful SMA
therapy. To test this objective, we chose to use adult mice car-
rying the human SMN2 transgene (Smn1tm1Hung/WT;SMN2tg/tg).
These mice are indistinguishable from wild-type animals. At 7.5 wk
of age, mice were treated twice by tail vein administration 2 d
apart with 18 μg/g of Pip6a-PMO or saline. Seven days post-
administration, tissues of the CNS and relevant peripheral tissues
were harvested and SMN expression was assessed. Transcript levels
of FLSMN2 relative to total SMN2 transcript levels were signifi-
cantly increased in all parts of the brain and spinal cord, as well as
in skeletal muscle and liver (Fig. 4 A–C). SMN protein levels were
augmented in skeletal muscles and liver only (Fig. 4D). Suboptimal
sensitivity in the protein detection method may have limited the
observation of increased levels in CNS tissues, which are predicted
to be lower than the levels observed in peripheral tissues. This
study demonstrates that our peptide delivery of antisense oligo-
nucleotides causing changes in transcripts within the adult CNS.
Discussion
In developing an effective SMA therapy, it is important to con-
sider the CNS and peripheral requirements for SMN restoration.
Multiple studies in SMA mouse models have generated conflicting
data regarding the importance of systemic versus CNS-only treatment
(11, 12, 43, 44, 47, 48). The single most important pathological
finding for SMA is the loss of lower motor neurons, and de-
nervation at the NMJ is the earliest pathological change in SMA
mice (37–41). However, reduced SMN expression has also been
observed to cause skeletal muscle (13, 14, 16) and vascular sys-
tem (19, 20, 49) defects in SMA mice, and SMN is involved in
general cellular functions, including small nuclear ribonucleic
protein (snRNP) biogenesis (13, 22–24) and glucose metabolism
(17, 18, 21). Thus, although delivery to the CNS is primordial for
SMA therapy, combined targeting of both the CNS and the
periphery has the potential of being the optimal approach. We
have shown that Pip6a-conjugated PMO heralds a potent therapeutic
Fig. 3. Rescue of SMA pathology in Pip6a-PMO–
administered SMA pups. (A) Representative confocal
images of NMJs from untreated SMA pups, un-
affected controls, and pups administered 5 μg/g or
10 μg/g of Pip6a-PMO PND0. Postsynaptic endplates
were stained in red (α-bungarotoxin) and neurons
were stained in green in neurofilament (2H3) and
synaptic vesicles (SV2). (Scale bar, 25 μm.) Reduced
innervation (open white triangle) and accumulation
of neurofilament (filled white triangle) were ob-
served in SMA-untreated pups. Partial innervation
(open yellow triangle) and poor arborization (white
arrow) were visible in Pip6a-PMO–treated pups. The
optimal complexity of terminal arborizations and
fully innervated NMJs is observable in unaffected
controls (yellow arrows). (B) NMJs were scored for
denervation, either partial or full, and plotted as the
percentage of total NMJs analyzed. (C) Postsynaptic
areas were quantified using ImageJ. Quantitative
levels of markers for apoptosis are shown: Pmaip1
(D) and Fas (E) relative transcripts in spinal cord of
PND7-treated and untreated mice, normalized to
mGapdh transcript levels. In B–E, data are repre-
sented as mean ± SEM (*P ≤ 0.05; **P ≤ 0.005; ***P ≤
0.0005 by Student’s t test in comparison to untreated
SMA mice).
Fig. 4. Pip6a-PMO administration in unaffected adult mice harboring the
human SMN2 allele (Smn1tm1Hung/WT;SMN2tg/tg). (A–C) Quantitative RT-PCR
from tissues of mice administered 18 mg/kg, i.v. 2 d apart. Tissues from brain
(A), spinal cord (B), and peripheral skeletal muscles and liver (C) were har-
vested 7 d postadministration. In all tissues, FLSMN2 expression was signifi-
cantly increased over saline-treated mice. (D) Protein expression of SMN in
tissues. Separate tissues of spinal cord and skeletal muscles were combined.
SMN protein was analyzed with Western blots for human SMN and mouse
β-tubulin. Data are represented as mean ± SEM (*P ≤ 0.005; **P ≤ 0.001;
***P ≤ 0.0001 by Student’s t test in comparison to saline-treated mice).











option combining the genetic precision of SSOs with the systemic
delivery efficacy of a small molecule. Systemic Pip6a-PMO treat-
ment demonstrates ultrahigh potency, with only a single 10-μg/g
dose at PND0 yielding a median survival of 167 d in severe SMA
pups and the longest lived mouse surviving 428 d, which is far be-
yond the greatest extension recorded for naked PMO (12) (Fig. 2A
and Table S1). This dramatic extension in survival is associated with
increased SMN expression in brain, spinal cord, and all examined
peripheral tissues; rescued levels of circulating IGF1; reduced NMJ
denervation; and decreased expression of apoptotic markers in the
spinal cord (Figs. 1 and 3). Furthermore, we were able to enhance
median survival to over 450 d with two 10-μg/g doses (Fig. 2B and
Table S1). Significantly enhanced survival in severe SMA models
has been reported using systemic administration of SSOs targeting
the ISS-N1 site. The best survival data published to date include
reports by Hua et al. (11), who reported a median survival of 248 d,
and by Zhou et al. (44), who reported a median survival of 261 d.
However, the former administered two doses of 160 mg/kg and the
latter used a single dose of 40 mg/kg. Pip6a delivery allows us to
reduce the dose required for maximum survival by at least fourfold,
an important step for generating clinically relevant compounds.
Current clinical trials (Ionis Pharmaceuticals) use intrathecal
delivery of a 2’-O-methoxyethyl (2’-MOE) SSO, primarily tar-
geting SMN expression in the CNS. In an open-label phase 2
study, infants with SMA were treated with SSO targeting ISS-N1
(Nusinerson, IONIS-SMNRX), which modestly improved their
median event-free age (age of permanent ventilation or death)
(50). More encouragingly, treated infants showed improvement
in muscle function and motor milestones. In a separate phase 2
study in children with SMA, the same SSO resulted in improved
mobility [6-min walk test) (51), upper limb mobility test (52), and
Hammersmith functional motor scale-expanded function (53)]
compared with pretreatment functions. F. Hoffman-La Roche in
Switzerland, PTC Therapeutics, and the SMA Foundation have
partnered to develop a small-molecule drug (RG7800) capable
of positively influencing exon 7 splicing systemically. This trial,
termedMoonfish, has been suspended because of safety concerns in
treated animals. However, Roche has a new similarly acting drug
(RG7916) for which they have initiated a phase 1 study to investigate
safety, tolerability, pharmacokinetics, and pharmacodynamics in
healthy volunteers. A related trial with a Novartis-sponsored orally
active small molecule that enhances SMN2 splicing, elevates full-
length SMN protein, and extends survival in a severe SMA mouse
model is also underway, sponsored by Novartis. The molecular
mechanism of action of this drug is via stabilization of the transient
double-stranded RNA structure formed by the SMN2 pre-mRNA
and U1 snRNP complex (54). It will be of great interest to compare
results of the CNS restoration of SMN protein (intrathecal SSO)
with the outcome of the combined peripheral and CNS restoration
of SMN protein level, because these trials could provide the
greatest indication in patients of the need for a systemic and/or
CNS treatment.
Although a previous study observed brain delivery of antisense
oligonucleotides with tagged dyes (55), we report the bona fide
activity of a CNS-peptide–delivered SSO. We have demonstrated
here the potent impact of peptide delivery on PMO SSO therapy.
In addition to SMA, other diseases for antisense oligonucleotide
therapies include ALS (56, 57), Huntington’s disease (58, 59),
and Parkinson’s disease (60, 61), which all ideally require both
systemic and CNS SSO delivery. Future work will focus on
extending further the clinical applications of Pip-PMOs.
Materials and Methods
Synthesis of Peptide-PMO Conjugates. Pip6a Ac-(RXRRBRRXRYQFLIRXRBRXRB)-
COOH was synthesized and conjugated to PMO as described previously (28). The
PMO sequence targeting ISS-N1 intron 7 (-10-27) (5′-ATTCACTTTCATAATGCTGG-
3′) and PMO scrambled (5′-ATTGTCTATCAAAATCCTGC-3′) was purchased from
Gene Tools LLC.
In Vitro Study. Human neuroblastoma SH-SY5Y cells were treated using 25,
50, 100, 250, and 500 nM oligonucleotides in 500 μL of full-serum DMEM and
analyzed for FLSMN2 mRNA expression 24 h later.
Animal Models. Experiments were carried out in the Biomedical Sciences Unit,
University of Oxford, according to procedures authorized by the UK Home
Office. SMA-like mouse strain FVB.Cg-Smn1tm1HungTg(SMN2)2Hung/J was
generated and maintained as previously described (33, 34). The intravenous
injections were performed by single (PND0) or double (PND0 and PND2)
administration via the facial vein. Doses of 2.5 μg/g (0.25 nmol/g), 5.0 μg/g
(0.5 nmol/g), and 10 μg/g (1 nmol/g) of Pip6a-PMO and 10 μg/g of PMO
(1.48 nmol/g) were diluted in 0.9% saline and given at a volume of 5 μL/g of
body weight. Treated mice were given mash and jelly as food supplementation.
Tail vein administration in adult mice was performed in unaffected mice
(Smn1tm1Hung/WT;SMN2tg/tg) at 7.5 wk of age. Two doses of 18 μg/g of Pip6a-PMO
or saline were given 2 d apart. Tissues were harvested 7 d postadministration.
Measuring Early Disease Phenotype.Weightswere taken daily, and overall health
was assessed. Following thehumaneendpoint,micewereeuthanizedaccording to
the approved procedure of rising CO2. Negative geotaxis was performed as pre-
viously described (35). Statistical significance was determined by a binomial test.
The hind-limb suspension tube test was performed as described in procedures for
preclinical studies by Translational Research in Europe – Assessment & Treatment
of Neuromuscular Diseases (35). For the purposes of reproducibility, factors such as
leg pulls and time were left out of the analysis. Statistical significance was de-
termined by Fisher’s test with Bonferroni correction in SPSS.
NMJ Immunohistochemistry. Animals treated with Pip6a-PMO were harvested
12 d postadministration (PND12). The TVA muscle was isolated, and immunohis-
tochemistry was performed on NMJs as previously described (42, 62). NMJs were
imaged using an Olympus FV1000 confocal microscope. Images were taken with a
40× objective as a z-stack. Only NMJs with fully observable postsynapses were
used for denervation counts. More than 300 NMJs were analyzed for full or partial
denervation per group, which was observed by the colocalization of presynaptic
neurons with postsynaptic acetylcholine receptors. The area of postsynaptic motor
endplates was measured using ImageJ (NIH) as previously published (63).
qPCR. RNA extraction from harvested tissues was carried out using TRIzol
reagent (Invitrogen), and cDNA was generated using an ABI High Capacity
cDNA Reverse Transcription Kit (Invitrogen) following the manufacturer’s
instructions. A qPCR reaction using Power SYBR Green Master Mix (Life
Technologies) was performed and analyzed on an Applied Biosystems
StepOnePlusTM real-time PCR system (Life Technologies). FLSMN2 and total
SMN2 transcripts were amplified using gene-specific primers (Table S3). Fas,
Pmaip1, and Gapdh were amplified using an Integrated DNA Technologies-
derived probe and primer set (Table S3).
Protein Extraction and Western Blot. Protein was harvested from ∼300 mg of
tissue homogenized into radioimmunoprecipitation buffer with complete
mini-proteinase inhibitors (Roche). Protein (30–40 μg) was probed for human
SMN protein using anti-SMN, clone SMN-KH monoclonal IgG1 (Millipore),
and mouse β-tubulin utilizing anti–β-actin monoclonal IgG2a (Sigma) and
secondary antibody IRDye 800CW goat anti-mouse IgG (LI-COR Biosciences).
Membranes were imaged on a LI-COR Odyssey FC imager and analyzed with
Image StudioTM software (LI-COR Biosciences).
IGF1 ELISA. Concentration of serum IGF1 was determined using aMurine IGF1
ELISA kit (900-K170; Peprotech) following the manufacturer’s instructions.
Clinical Biochemistry. Serum samples from mice administered Pip6a-PMO or
PMO at PND0 and PND0/2were extracted from the jugular vein upon harvest at
PND7, and analysis of toxicity biomarkerswas performed by a clinical pathology
laboratory (Mary Lyon Centre, Medical Research Council, Harwell, UK).
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